Literature DB >> 15003790

Expression of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in rat osteoporosis induced by immunosuppressant FK506.

J Fukunaga1, T Yamaai, E Yamachika, Y Ishiwari, H Tsujigiwa, K Sawaki, Y J Lee, T Ueno, S Kirino, N Mizukawa, S Takagi, N Nagai, T Sugahara.   

Abstract

Immunosuppressant drugs are currently required by transplant recipients for the remainder of their lives, despite the many adverse effects associated with these therapies. Acute osteoporosis is one such effect, and a reproducible osteoporosis model has been established through the administration of the immunosuppressant drug FK506 in rats. The cause of this osteoporosis has been shown to be abnormal osteoclast proliferation, altering the process of bone remodeling. However, the reasons why FK506 induces osteoclast proliferation and whether this process is mediated by cytokine changes or an increase in bone resorption factors have been unclear. An investigation was therefore conducted focusing on the recent discoveries of osteoclast differentiation factor (ODF) and osteoclastogenesis inhibitory factor (OCIF). These factors led to elucidation of the osteoclast differentiation-maturation mechanism. An osteoporosis model was produced in rats utilizing intramuscular FK506 injection (1 mg/kg) for 28 consecutive days. Trabecular bone resorption was observed inferior to enchondral ossification in the FK506 group, and tartrate resistant acid phosphatase (TRAP) staining revealed a clear increase in osteoclasts at the site of enchondral ossification, relative to the control group. Real-time PCR and in situ hybridization (ISH) demonstrated minimal differences in OCIF expression between control and the treatment groups. However, Real-time PCR revealed clearly increased ODF expression in the treatment group. ODF expression was also shown to be increased in the treatment group using ISH. This was histologically consistent with a region of osteoclast proliferation inferior to enchondral ossification. The results of this study support the hypothesis that FK506-mediated osteoporosis occurs by action of the drug on osteoclasts, promoting expression of ODF messenger ribonucleic acid (mRNA) and thus prompting osteoclast differentiation and maturation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15003790     DOI: 10.1016/j.bone.2003.05.003

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  7 in total

1.  A collagen-based hydrogel containing tacrolimus for bone tissue engineering.

Authors:  Mir Hamed Nabavi; Majid Salehi; Arian Ehterami; Farshid Bastami; Hassan Semyari; Maryam Tehranchi; Mir Ahmad Nabavi; Hossein Semyari
Journal:  Drug Deliv Transl Res       Date:  2020-02       Impact factor: 4.617

2.  Effects of bisphosphonate treatment on bone repair under immunosuppression using cyclosporine A in adult rats.

Authors:  T Matsunaga; M Shigetomi; T Hashimoto; H Suzuki; T Gondo; H Tanaka; T Sugiyama; T Taguchi
Journal:  Osteoporos Int       Date:  2007-05-10       Impact factor: 4.507

3.  Suppressive effects of 1,4-dihydroxy-2-naphthoic acid administration on bone resorption.

Authors:  M Matsubara; E Yamachika; H Tsujigiwa; N Mizukawa; T Ueno; J Murakami; N Ishida; Y Kaneda; N Shirasu; S Takagi
Journal:  Osteoporos Int       Date:  2009-10-08       Impact factor: 4.507

4.  FK506 prevented bone loss in streptozotocin-induced diabetic rats via enhancing osteogenesis and inhibiting adipogenesis.

Authors:  Li-Hua Ni; Ri-Ning Tang; Cheng Yuan; Kai-Yun Song; Li-Ting Wang; Xiao-Chen Wang; Yu-Xia Zhang; Xiao-Liang Zhang; Dong-Dong Zhu; Bi-Cheng Liu
Journal:  Ann Transl Med       Date:  2019-06

5.  Effects of immunosuppressants, FK506 and cyclosporin A, on the osteogenic differentiation of rat mesenchymal stem cells.

Authors:  Yu-Kyung Byun; Kyoung-Hwa Kim; Su-Hwan Kim; Young-Sung Kim; Ki-Tae Koo; Tai-Il Kim; Yang-Jo Seol; Young Ku; In-Chul Rhyu; Yong-Moo Lee
Journal:  J Periodontal Implant Sci       Date:  2012-06-30       Impact factor: 2.614

6.  Sirolimus and tacrolimus rather than cyclosporine A cause bone loss in healthy adult male rats.

Authors:  Mercedes Rubert; Mercedes Montero; David Guede; Jose-Ramón Caeiro; Marta Martín-Fernández; Manuel Díaz-Curiel; Concepción de la Piedra
Journal:  Bone Rep       Date:  2015-05-14

7.  MicroRNA expression analysis during FK506-induced osteogenic differentiation in rat bone marrow stromal cells.

Authors:  Jing Zhang; Xiaoping Yu; Youcheng Yu; Yiming Gong
Journal:  Mol Med Rep       Date:  2017-05-31       Impact factor: 2.952

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.